3 completed, 1 recruiting, 1 withdrawn. 4 Phase 2, 2 Phase 1.
By phase and status
Follow Boserolimab: new trials by email Literature Review of Boserolimab trials Research Report on Boserolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
Pembrolizumab, Paclitaxel, Carboplatin - Early Triple Negative Breast Cancer | Phase 2 | Withdrawn | | 2025-03-26 | 2026-02-19 |
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Pembrolizumab, MK-4830, Boserolimab - Small Cell Lung Cancer | Phase 2 | Completed | 122 | 2021-07-15 | 2026-08-13 |
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Pembrolizumab, Boserolimab, MK-4830 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | 128 | 2020-01-21 | 2026-06-26 |
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Pembrolizumab, Carboplatin, Paclitaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Recruiting | 450 | 2019-12-19 | 2026-10-29 |
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Boserolimab, Pembrolizumab, Pemetrexed - Pharmacokinetics, Solid Tumor | Phase 1 | Completed | 182 | 2018-02-18 | 2025-11-05 |
Conditions studied
Parkinson Disease 4, Autosomal Dominant Lewy Body (4) · Carcinoma, Non-Small-Cell Lung (3) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Small Cell Lung Carcinoma (1)
Sponsors
Merck Sharp & Dohme LLC (5)
Countries
United States (5) · Israel (4) · South Korea (4) · Spain (4) · Hungary (3) · Italy (3) · Poland (3) · Taiwan (3) · Canada (2) · Austria (1) · Chile (1) · Netherlands (1) · Russia (1) · Switzerland (1) · Ukraine (1)
NIH funding
2023 (3), 2017 (1)